14 Výsledek
FIELD OF THE INVENTION
The present invention relates to the treatment of tumors exhibiting B-glucuronidase activity by means of glucuronides having toxic aglycones and, more particularly, to an improvement of such process which eliminates damage to the kidneys. The toxic aglycones may incorporate a
TECHNICAL FIELD
The present invention relates to the treatment of tumors exhibiting .beta.-glucuronidase activity by means of glucuronides having toxic aglycones and, more particularly, to an improvement of such processes which eliminates damage to the kidneys. The toxic aglycones may incorporate a
FIELD OF THE INVENTION
The present invention relates to a method of diagnosing tumors which are treatable by means of glucuronides having toxic aglycones and, more particularly, to a method of diagnosing tumors exhibiting .beta.- glucuronidase activity by means of a urine test.
BACKGROUND OF THE
FIELD OF THE INVENTION
The present invention relates to a method and composition for increasing the sensitivity of malignant tumors to chemotherapeutic agents.
BACKGROUND OF THE INVENTION
Chemotherapy, particularly with a combination of anti-cancer agents, is the treatment of choice for delocalized
FIELD OF THE INVENTION
The present invention is directed to a method and composition for treating tumors exhibiting .beta.-glucuronidase activity, and, more specifically, to a method and composition for treating tumors exhibiting .beta.-glucuronidase activity by preventing metabolism of tumor
FIELD OF THE INVENTION
The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and .beta.-glucuronidase activity. The invention is further directed to methods and compositions for treating tumors having high
FIELD OF THE INVENTION
The present invention relates to inactivators of O.sup.6-alkylguanine-DNA alkyltransferase (AGT) and prodrugs of such inactivators. The prodrugs are cleaved by the beta-glucuronidase enzyme found in tumor cells or co-administered to the patient, and are targeted for use in
FIELD OF THE INVENTION
The present invention relates to the treatment of certain bacterial infections having .beta.-glucuronidase activity. The present invention further relates to a new class of glucuronides whose aglycone's activity or water solubility is pH dependent as well as the method of
FIELD OF THE INVENTION
The present invention relates to the treatment of tumors exhibiting .beta.-glucuronidase activity by means of glucuronides having toxic aglycones and, more particularly, to an improvement of such processes which eliminates damage to the kidneys. The invention further relates
BACKGROUND OF THE INVENTION
One of the major obstacles of cancer chemotherapy is lack of tumor specificity which leads to life-threatening toxicity. Tumor selectivity can be enhanced by creating relatively non-toxic prodrugs that are selectively activated in the tumor microenvironment by enzymes,
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose
BACKGROUND OF THE INVENTION
Breast cancer kills thousands of women annually. While surgical intervention has saved the lives of many women, radical and partial mastectomies often prove physically and emotionally debilitating. Indeed, surgery, even when combined with chemotherapy, may still expose